论文部分内容阅读
目的:探讨应用鱼肝油酸钠碘油抗癌药乳剂加明胶海绵同时栓塞肝动脉治疗原发性肝癌的疗效。方法:对不能手术切除的73例中晚期原发性肝癌病人进行了肝动脉化疗栓塞治疗。对这些病人随访6～18个月。结果:显示肿瘤直径缩小50%者占64.4%(47/73)、25%～50%之间占24.6%(18/73)、<25%或肿块无变化者占11%(8/73),无1例治疗后肿块继续增大。AFP 下降者占80.8%(42/52),其中降至正常者占51.9%(27/52)。6、12、18个月生存率分别为100%、75.3%及57.3%。全部病人对鱼肝油酸钠-碘油乳剂耐受良好。无严重合并症发生。结论:鱼肝油酸钠-碘油乳剂加明胶海绵栓塞肝动脉治疗肝癌是安全有效的。
OBJECTIVE: To investigate the efficacy of hepatic arterial embolization in the treatment of hepatocellular carcinoma with hepatolipid sodium lipiodol anticancer drug emulsion plus gelatin sponge. METHODS: Hepatic arterial chemoembolization was performed on 73 patients with advanced primary liver cancer who could not be surgically resected. The patients were followed up for 6 to 18 months. Results: The results showed that the tumor diameter reduced by 50% accounted for 64.4% (47/73), 25% to 50% accounted for 24.6% (18/73), <25% or 11% of patients with no change in the tumor (8/73) None of the patients continued to increase in mass after treatment. The decrease in AFP accounted for 80.8% (42/52), of which 51.9% (27/52) decreased to normal. The 6, 12, and 18-month survival rates were 100%, 75.3%, and 57.3%, respectively. All patients had good tolerance to sodium morrhuate-lipiodol emulsion. No serious complications occurred. Conclusion: It is safe and effective to treat hepatocellular carcinoma by hepatic sodium morrhuate-lipiodol emulsion plus gelatin sponge embolization.